Compare Stocks: INBX, RYTM, SRRK, and CGON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.67 +0.5%	$73.63	$29.85 ▼ $80.97	$6.62B	0.24	708,449 shs	282,520 shs
INBX Inhibrx Biosciences	$121.17 -0.9%	$97.26	$26.19 ▼ $155.29	$1.78B	3.66	292,735 shs	192,159 shs
RYTM Rhythm Pharmaceuticals	$102.74 -2.0%	$109.60	$74.50 ▼ $122.20	$7.19B	1.97	506,335 shs	466,904 shs
SRRK Scholar Rock	$55.33 -1.1%	$53.44	$27.07 ▼ $61.76	$6.81B	0.67	1.04 million shs	658,041 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.46%	+0.44%	+3.11%	+39.00%	+160.45%
INBX Inhibrx Biosciences	-0.89%	-1.82%	+44.44%	+39.26%	+335.86%
RYTM Rhythm Pharmaceuticals	-2.05%	-4.13%	-7.20%	+18.91%	+1.03%
SRRK Scholar Rock	-1.09%	-4.27%	+15.34%	+24.90%	+60.94%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$74.67 +0.5%	$73.63	$29.85 ▼ $80.97	$6.62B	0.24	708,449 shs	282,520 shs
INBX Inhibrx Biosciences	$121.17 -0.9%	$97.26	$26.19 ▼ $155.29	$1.78B	3.66	292,735 shs	192,159 shs
RYTM Rhythm Pharmaceuticals	$102.74 -2.0%	$109.60	$74.50 ▼ $122.20	$7.19B	1.97	506,335 shs	466,904 shs
SRRK Scholar Rock	$55.33 -1.1%	$53.44	$27.07 ▼ $61.76	$6.81B	0.67	1.04 million shs	658,041 shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.46%	+0.44%	+3.11%	+39.00%	+160.45%
INBX Inhibrx Biosciences	-0.89%	-1.82%	+44.44%	+39.26%	+335.86%
RYTM Rhythm Pharmaceuticals	-2.05%	-4.13%	-7.20%	+18.91%	+1.03%
SRRK Scholar Rock	-1.09%	-4.27%	+15.34%	+24.90%	+60.94%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.77	Moderate Buy	$83.18	11.40% Upside
INBX Inhibrx Biosciences	2.50	Moderate Buy	$197.50	62.99% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	37.35% Upside
SRRK Scholar Rock	3.13	Buy	$58.77	6.22% Upside

Current Analyst Ratings Breakdown

Latest INBX, RYTM, SRRK, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/27/2026	INBX Inhibrx Biosciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform
8/24/2026	INBX Inhibrx Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$245.00
8/21/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00
8/10/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/10/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
8/7/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$76.00
8/7/2026	SRRK Scholar Rock	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $60.00
8/7/2026	CGON CG Oncology	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $79.00
8/7/2026	CGON CG Oncology	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $85.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$6.23M	1,062.74	N/A	N/A	$11.61 per share	6.43
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	($3.60) per share	N/A
RYTM Rhythm Pharmaceuticals	$239.92M	29.35	N/A	N/A	$1.50 per share	68.49
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.08 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
INBX Inhibrx Biosciences	-$140.05M	-$8.88	N/A	N/A	N/A	N/A	-563.90%	-83.48%	11/13/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)

Latest INBX, RYTM, SRRK, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	INBX Inhibrx Biosciences	-$2.28	-$2.34	-$0.06	-$2.34	N/A	N/A
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
INBX Inhibrx Biosciences	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
INBX Inhibrx Biosciences	12.58	5.07	5.07
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SRRK Scholar Rock	0.77	7.02	7.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
INBX Inhibrx Biosciences	82.46%
RYTM Rhythm Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
INBX Inhibrx Biosciences	18.26%
RYTM Rhythm Pharmaceuticals	5.90%
SRRK Scholar Rock	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	88.64 million	84.39 million	Optionable
INBX Inhibrx Biosciences	166	14.72 million	12.03 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
SRRK Scholar Rock	140	121.79 million	109.24 million	Optionable

INBX, RYTM, SRRK, and CGON Headlines

Recent News About These Companies

Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK

September 5 at 4:07 AM | marketbeat.com

Scholar Rock Gets FDA Fast Track, Orphan Drug Designations for Muscular Disorder Drug

September 2 at 8:39 PM | finance.yahoo.com

Senator Investment Group LP Acquires New Stake in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

122,223 Shares in Scholar Rock Holding Corporation $SRRK Acquired by The Manufacturers Life Insurance Company

August 31, 2026 | marketbeat.com

Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK

August 31, 2026 | marketbeat.com

104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc

August 30, 2026 | marketbeat.com

Algert Global LLC Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK

August 29, 2026 | marketbeat.com

Jupiter Topco LLC Invests $123.28 Million in Scholar Rock Holding Corporation $SRRK

August 27, 2026 | marketbeat.com

96,285 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Artia Global Partners LP

August 27, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Shares Up 5.8% - Still a Buy?

August 26, 2026 | marketbeat.com

EFG International AG Takes Position in Scholar Rock Holding Corporation $SRRK

August 26, 2026 | marketbeat.com

Nicholas Investment Partners LP Purchases New Position in Scholar Rock Holding Corporation $SRRK

August 25, 2026 | marketbeat.com

9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc.

August 25, 2026 | marketbeat.com

Scholar Rock (NASDAQ:SRRK) Sets New 52-Week High - Should You Buy?

August 24, 2026 | marketbeat.com

303,268 Shares in Scholar Rock Holding Corporation $SRRK Bought by Deutsche Bank AG

August 23, 2026 | marketbeat.com

Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story?

August 22, 2026 | finance.yahoo.com

Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus

August 21, 2026 | kalkinemedia.comK

Scholar Rock Removes Catalent Indiana From Apitegromab BLA as Fill-Finish Facility

August 21, 2026 | finance.yahoo.com

Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission

August 21, 2026 | msn.com

Scholar Rock Provides Update on Global Apitegromab Regulatory Progress Across U.S., Europe, and Japan

August 21, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, RYTM, SRRK, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$74.67 +0.34 (+0.46%)

As of 09/4/2026 04:00 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Inhibrx Biosciences NASDAQ:INBX

$121.17 -1.09 (-0.89%)

As of 09/4/2026 04:00 PM Eastern

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$102.74 -2.15 (-2.05%)

As of 09/4/2026 04:00 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Scholar Rock NASDAQ:SRRK

$55.33 -0.61 (-1.09%)

As of 09/4/2026 04:00 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INBX, RYTM, SRRK, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INBX, RYTM, SRRK, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INBX, RYTM, SRRK, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, RYTM, SRRK, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Inhibrx Biosciences NASDAQ:INBX

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INBX, RYTM, SRRK, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INBX, RYTM, SRRK, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INBX, RYTM, SRRK, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

INBX, RYTM, SRRK, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Inhibrx Biosciences NASDAQ:INBX

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools